München
06.02.26 | 08:38
12,900 Euro
-0,39 % -0,050
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,600 | 12,850 | 07.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEXSTIM Aktie jetzt für 0€ handeln | |||||
| Mo | Nexstim Oyj: Nexstim Receives System Order from Distributor in India | 144 | GlobeNewswire (Europe) | Press release, Helsinki, 2 February 2026 at 9 AM (EET)
Nexstim Receives System Order from Distributor in India
Nexstim Plc ("Nexstim" or "Company") has received an order for an NBS System 5 through... ► Artikel lesen | |
| 30.12.25 | Nexstim Receives U.S. Order For Two NBS 6 Therapy Systems | 5 | RTTNews | ||
| 30.12.25 | Nexstim Oyj: US Customer Orders Two Nexstim NBS 6 Therapy Systems | 322 | GlobeNewswire (Europe) | Press release, Helsinki, 30 December 2025 at 9 AM (EET)
US Customer Orders Two Nexstim NBS 6 Therapy Systems
Nexstim Plc ("Nexstim" or "Company") has received an order for two NBS 6 therapy systems... ► Artikel lesen | |
| 23.12.25 | Nexstim Oyj: Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc. | 130 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 23 December 2025 at 9 AM (EET)
Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc.
Nexstim Plc ("Nexstim"... ► Artikel lesen | |
| 16.09.25 | Nexstim Oyj: Nexstim Receives NBS 5+ System Order from Therapy Customer in United States | 162 | GlobeNewswire (Europe) | Press release, Helsinki, 16 September 2025 at 9 AM (EEST)
Nexstim Receives NBS 5+ System Order from Therapy Customer in United States
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an... ► Artikel lesen | |
| 15.08.25 | Nexstim Oyj: Nexstim Plc Half-year Report January 1 - June 30, 2025 (unaudited) | 172 | GlobeNewswire (Europe) | NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 - JUNE 30, 2025 (UNAUDITED)
Company announcement, Helsinki, August 15, 2025 at 9 am (EEST)
NEXSTIM ACCELERATED GROWTH AND IMPROVED PROFITABILITY IN THE FIRST HALF... ► Artikel lesen | |
| 08.08.25 | Nexstim Oyj: Nexstim Receives NBS System 5 Order from India | 350 | GlobeNewswire (Europe) | Press release, Helsinki, 8 August 2025 at 10 AM (EEST)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an Indian distributor.
The end customer is a hospital... ► Artikel lesen | |
| 30.06.25 | Nexstim Oyj: Nexstim Plc Signs Exclusivity Agreement with Sinaptica Therapeutics, Inc. as Part of Planned Alzheimer's Collaboration | 137 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 30 June 2025 at 9 AM (EEST)
Nexstim Plc Signs Exclusivity Agreement with Sinaptica Therapeutics, Inc. as Part of Planned Alzheimer's Collaboration
Nexstim Plc (NXTMH:HEX)... ► Artikel lesen | |
| 23.06.25 | Nexstim Oyj: Nexstim Receives NBS System 5 Order from a University Hospital in Germany | 233 | GlobeNewswire (Europe) | Press release, Helsinki, 23 June 2025 at 9 AM (EEST)
Nexstim Receives NBS System 5 Order from a University Hospital in Germany
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order... ► Artikel lesen | |
| 05.05.25 | Nexstim Oyj: Nexstim Plc Business Update Q1 2025 | 304 | GlobeNewswire (Europe) | Press release, Helsinki, 5 May 2025, at 9 AM (EEST)
Nexstim Plc Business Update Q1 2025
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the key highlights of the Company's business operations... ► Artikel lesen | |
| 27.02.25 | Nexstim Oyj: Nexstim Plc's Financial Statements Bulletin 2024 | 327 | GlobeNewswire (Europe) | Company announcement, Helsinki 27 February 2025 at 9 am (EET)
NEXSTIM PLC'S FINANCIAL STATEMENTS BULLETIN 2024
NEXSTIM CONTINUED PROFITABLE GROWTH AND SIGNED SIGNIFICANT PARTNERSHIPS
July-December 2024
The... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| VERU | 2,340 | +4,46 % | Veru Inc.: Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th | ||
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | HV-Termine: Hauptversammlungen bei Adv. Blockchain, Aurubis, Fortec, Schott, Siemens, Healthineers, Stabilus, TUI | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | BREAKING: Hims & Hers verschärft Preisdruck bei Novo Nordisk - Aktie beschleunigt Talfahrt | Der dänische Biopharma-Riese ist erst seit wenigen Wochen mit seinem Appetitzügler Wegovy als Tablette auf dem US-Markt und sieht sich einem massiven Preisdruck ausgesetzt. Das Telehealth-Unternehmen... ► Artikel lesen |
NEXSTIM OYJ gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,050 (-0,39 %) liegt der Kurs bei 12,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXSTIM OYJ finden Sie auf Wallstreet Online.